Skip to main content
. Author manuscript; available in PMC: 2024 Jan 3.
Published in final edited form as: Brain Res. 2021 Nov 10;1774:147721. doi: 10.1016/j.brainres.2021.147721

Fig. 5.

Fig. 5.

Intrathecal CB2R agonist, AM1241 and AM1710 treatment decreases TRPV1 immunofluorescence in neuropathic rat spinal cord and DRG. A, B, In the dorsal horn of the spinal cord taken from unilateral CCI rats treated with intrathecal (i.t.) CB2R agonist AM1241, TRPV1 IR is bilaterally decreased. C, D, TRPV1 IR is bilaterally decreased in the dorsal horn of the spinal cord taken from ipsilateral CCI rats given i.t. CB2R agonist AM1710. E, F, In DRG, TRPV1 IR is increased following CCI-induced neuropathy and decreased with i.t. AM1241 in both ipsilateral and contralateral DRG. H, I, TRPV1 IR is increased under CCI-induced neuropathy and decreased with i.t. AM1710 in both ipsilateral and contralateral DRG. *p < 0.05 vs. Sham vehicle-injected control, #p < 0.05 vs. CCI Vehicle-injected control (Tukey’s test), and results are mean ± S.E.M., n = 3 rats/group.